LECT2 amyloidosis: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{Infobox medical condition | |||
[[File:Amyloidosis,_Node,_Congo_Red.jpg| | | name = LECT2 amyloidosis | ||
| image = [[File:Amyloidosis,_Node,_Congo_Red.jpg|left|thumb|Amyloid deposits in tissue stained with Congo red]] | |||
| caption = Amyloid deposits in tissue stained with Congo red | |||
| specialty = [[Nephrology]], [[Rheumatology]] | |||
| symptoms = [[Kidney failure]], [[proteinuria]], [[joint pain]] | |||
| onset = Typically in [[adulthood]] | |||
| duration = [[Chronic (medicine)|Chronic]] | |||
| causes = Deposition of [[leukocyte cell-derived chemotaxin 2]] protein | |||
| risks = [[Genetic predisposition]], [[chronic inflammation]] | |||
| diagnosis = [[Biopsy]], [[immunohistochemistry]], [[genetic testing]] | |||
| differential = Other forms of [[amyloidosis]], [[chronic kidney disease]] | |||
| treatment = [[Supportive care]], [[dialysis]], [[kidney transplantation]] | |||
| prognosis = Variable, depending on extent of organ involvement | |||
| frequency = Rare | |||
}} | |||
'''LECT2 amyloidosis''' is a form of [[amyloidosis]] characterized by the deposition of [[leukocyte cell-derived chemotaxin 2]] (LECT2) protein in various tissues, leading to organ dysfunction. It is a rare condition that primarily affects the [[kidney]], but can also involve other organs such as the [[liver]] and [[spleen]]. | '''LECT2 amyloidosis''' is a form of [[amyloidosis]] characterized by the deposition of [[leukocyte cell-derived chemotaxin 2]] (LECT2) protein in various tissues, leading to organ dysfunction. It is a rare condition that primarily affects the [[kidney]], but can also involve other organs such as the [[liver]] and [[spleen]]. | ||
== Pathophysiology == | == Pathophysiology == | ||
LECT2 is a protein that is normally produced by the [[liver]] and plays a role in [[immune response]] and [[inflammation]]. In LECT2 amyloidosis, the LECT2 protein misfolds and aggregates into amyloid fibrils, which are deposited in tissues. This deposition disrupts normal tissue architecture and function, leading to organ damage. | LECT2 is a protein that is normally produced by the [[liver]] and plays a role in [[immune response]] and [[inflammation]]. In LECT2 amyloidosis, the LECT2 protein misfolds and aggregates into amyloid fibrils, which are deposited in tissues. This deposition disrupts normal tissue architecture and function, leading to organ damage. | ||
== Clinical Presentation == | == Clinical Presentation == | ||
Patients with LECT2 amyloidosis often present with symptoms related to kidney dysfunction, such as [[proteinuria]], [[edema]], and [[hypertension]]. Some patients may also exhibit liver dysfunction or splenomegaly. The disease is often diagnosed in older adults and has been reported more frequently in individuals of Hispanic descent. | Patients with LECT2 amyloidosis often present with symptoms related to kidney dysfunction, such as [[proteinuria]], [[edema]], and [[hypertension]]. Some patients may also exhibit liver dysfunction or splenomegaly. The disease is often diagnosed in older adults and has been reported more frequently in individuals of Hispanic descent. | ||
== Diagnosis == | == Diagnosis == | ||
The diagnosis of LECT2 amyloidosis is confirmed by [[biopsy]] of affected tissue, typically the kidney, showing amyloid deposits. These deposits are identified using [[Congo red staining]], which reveals apple-green birefringence under polarized light. Immunohistochemistry or mass spectrometry can be used to specifically identify LECT2 as the amyloid protein. | The diagnosis of LECT2 amyloidosis is confirmed by [[biopsy]] of affected tissue, typically the kidney, showing amyloid deposits. These deposits are identified using [[Congo red staining]], which reveals apple-green birefringence under polarized light. Immunohistochemistry or mass spectrometry can be used to specifically identify LECT2 as the amyloid protein. | ||
== Treatment == | == Treatment == | ||
There is currently no specific treatment for LECT2 amyloidosis. Management focuses on controlling symptoms and complications, such as [[hypertension]] and [[chronic kidney disease]]. In some cases, [[kidney transplantation]] may be considered for patients with end-stage renal disease. | There is currently no specific treatment for LECT2 amyloidosis. Management focuses on controlling symptoms and complications, such as [[hypertension]] and [[chronic kidney disease]]. In some cases, [[kidney transplantation]] may be considered for patients with end-stage renal disease. | ||
== Prognosis == | == Prognosis == | ||
The prognosis of LECT2 amyloidosis varies depending on the extent of organ involvement and the patient's overall health. Kidney involvement often leads to progressive renal failure, which can significantly impact survival and quality of life. | The prognosis of LECT2 amyloidosis varies depending on the extent of organ involvement and the patient's overall health. Kidney involvement often leads to progressive renal failure, which can significantly impact survival and quality of life. | ||
== See also == | |||
== | |||
* [[Amyloidosis]] | * [[Amyloidosis]] | ||
* [[Kidney disease]] | * [[Kidney disease]] | ||
* [[Proteinuria]] | * [[Proteinuria]] | ||
* [[Hypertension]] | * [[Hypertension]] | ||
[[File:Creatinine_levels.jpg|Graph showing creatinine levels over time|left|thumb]] | |||
[[File:Creatinine_levels.jpg|Graph showing creatinine levels over time|thumb | |||
== See Also == | == See Also == | ||
* [[Leukocyte cell-derived chemotaxin 2]] | * [[Leukocyte cell-derived chemotaxin 2]] | ||
* [[Congo red staining]] | * [[Congo red staining]] | ||
* [[Immunohistochemistry]] | * [[Immunohistochemistry]] | ||
[[Category:Amyloidosis]] | [[Category:Amyloidosis]] | ||
[[Category:Kidney diseases]] | [[Category:Kidney diseases]] | ||
Latest revision as of 00:33, 8 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC
| LECT2 amyloidosis | |
|---|---|
 | |
| Synonyms | N/A |
| Pronounce | N/A |
| Specialty | Nephrology, Rheumatology |
| Symptoms | Kidney failure, proteinuria, joint pain |
| Complications | N/A |
| Onset | Typically in adulthood |
| Duration | Chronic |
| Types | N/A |
| Causes | Deposition of leukocyte cell-derived chemotaxin 2 protein |
| Risks | Genetic predisposition, chronic inflammation |
| Diagnosis | Biopsy, immunohistochemistry, genetic testing |
| Differential diagnosis | Other forms of amyloidosis, chronic kidney disease |
| Prevention | N/A |
| Treatment | Supportive care, dialysis, kidney transplantation |
| Medication | N/A |
| Prognosis | Variable, depending on extent of organ involvement |
| Frequency | Rare |
| Deaths | N/A |
LECT2 amyloidosis is a form of amyloidosis characterized by the deposition of leukocyte cell-derived chemotaxin 2 (LECT2) protein in various tissues, leading to organ dysfunction. It is a rare condition that primarily affects the kidney, but can also involve other organs such as the liver and spleen.
Pathophysiology[edit]
LECT2 is a protein that is normally produced by the liver and plays a role in immune response and inflammation. In LECT2 amyloidosis, the LECT2 protein misfolds and aggregates into amyloid fibrils, which are deposited in tissues. This deposition disrupts normal tissue architecture and function, leading to organ damage.
Clinical Presentation[edit]
Patients with LECT2 amyloidosis often present with symptoms related to kidney dysfunction, such as proteinuria, edema, and hypertension. Some patients may also exhibit liver dysfunction or splenomegaly. The disease is often diagnosed in older adults and has been reported more frequently in individuals of Hispanic descent.
Diagnosis[edit]
The diagnosis of LECT2 amyloidosis is confirmed by biopsy of affected tissue, typically the kidney, showing amyloid deposits. These deposits are identified using Congo red staining, which reveals apple-green birefringence under polarized light. Immunohistochemistry or mass spectrometry can be used to specifically identify LECT2 as the amyloid protein.
Treatment[edit]
There is currently no specific treatment for LECT2 amyloidosis. Management focuses on controlling symptoms and complications, such as hypertension and chronic kidney disease. In some cases, kidney transplantation may be considered for patients with end-stage renal disease.
Prognosis[edit]
The prognosis of LECT2 amyloidosis varies depending on the extent of organ involvement and the patient's overall health. Kidney involvement often leads to progressive renal failure, which can significantly impact survival and quality of life.
See also[edit]
